Soligenix

Soligenix acquires novel innate defense regulator clinical program

Tuesday, December 18, 2012 09:44 AM

Soligenix, a Princeton, N.J.-based development stage biopharmaceutical company, has acquired a novel drug technology, known as SGX94, representing a unique approach to modulation of the innate immune system. 

More... »

FDA grants Soligenix Fast Track designation for SGX203 for Crohn's disease

Friday, November 9, 2012 12:44 PM

Soligenix, a development stage biopharmaceutical company based in Princeton, N.J., announced that its drug SGX203, for the treatment of mild-to-moderate pediatric Crohn's disease, has received Fast Track designation from the FDA.

More... »

Soligenix reports positive phase Ib results with Ricin toxin vaccine

Tuesday, September 4, 2012 08:43 AM

Soligenix, a development stage biopharmaceutical company based in Princeton, N.J., released results of a phase Ib trial of an aluminum hydroxide (Alum) adjuvanted formulation of RiVax, designed to improve the immunogenicity of the vaccine.

More... »

Soligenix, IDRI to develop thermostabilized biodefense vaccines

Wednesday, June 27, 2012 09:44 AM

Soligenix, a development stage biopharmaceutical company, has entered into a collaboration with the Infectious Disease Research Institute (IDRI) of Seattle, Wash., to develop select biodefense vaccines using IDRI's potent and safe synthetic adjuvants in conjunction with Soligenix's proprietary subunit proteins and thermostability platform, ThermoVax. 

More... »

Soligenix demonstrates proof of concept with vaccine technology

Tuesday, February 7, 2012 10:49 AM

Soligenix, a development-stage biopharmaceutical company, has released results from pre-clinical studies of its proprietary vaccine thermostabilization technology indicating that Soligenix is able to produce stable vaccine formulations using adjuvants, protein immunogens and other components that ordinarily would not withstand long temperature variations exceeding customary refrigerated storage conditions.

More... »

Soligenix anthrax vaccine shows robust stability

Sunday, January 22, 2012 11:17 AM

Soligenix, a development-stage biopharmaceutical company, shared results from long-term stability studies of its proprietary DNI (dominant negative inhibitor) anthrax rPA (recombinant protective antigen) subunit protein vaccine, known as SGX204.

More... »

Soligenix, Harvard University partner to develop next generation anthrax vaccine

Thursday, December 15, 2011 04:15 PM

Soligenix, a development stage biopharmaceutical company, has initiated a next generation anthrax vaccine development program pursuant to a field-exclusive option agreement with Harvard University to negotiate a license under patent rights that cover prophylactic uses of a modified anthrax toxin protein. Initial development work will be covered pursuant to a previously issued $9.4 million National Institute of Allergy and Infectious Disease (NIAID) grant enabling development of thermo-stable ricin and anthrax vaccines.

More... »